[
  {
    "sourceRefId": "ref-001",
    "filename": "Caswell_et_al.pdf",
    "site": "bone",
    "metricName": null,
    "value": null,
    "unit": "year",
    "notes": "Giuliani J, Bonetti A",
    "pageHint": 7,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-001",
    "filename": "Caswell_et_al.pdf",
    "site": "bone",
    "metricName": null,
    "value": 2014,
    "unit": null,
    "notes": "Giuliani J, Bonetti A",
    "pageHint": 7,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-001",
    "filename": "Caswell_et_al.pdf",
    "site": "lung",
    "metricName": null,
    "value": 1127,
    "unit": null,
    "notes": "An evaluation of algorithms for\nidentifying  metastatic  breast,  lung,  or  colorectal  cancer  in  administrative\nclaims data.Med Care",
    "pageHint": 7,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-001",
    "filename": "Caswell_et_al.pdf",
    "site": "lung",
    "metricName": null,
    "value": 1138,
    "unit": null,
    "notes": "An evaluation of algorithms for\nidentifying  metastatic  breast,  lung,  or  colorectal  cancer  in  administrative\nclaims data.Med Care",
    "pageHint": 7,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-001",
    "filename": "Caswell_et_al.pdf",
    "site": "lung",
    "metricName": null,
    "value": 62,
    "unit": null,
    "notes": "An evaluation of algorithms for\nidentifying  metastatic  breast,  lung,  or  colorectal  cancer  in  administrative\nclaims data.Med Care",
    "pageHint": 7,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-002",
    "filename": "Lord_et_ al.pdf",
    "site": "metastases",
    "metricName": null,
    "value": 5,
    "unit": "years",
    "notes": "This  research  will  extend  existing  popu-\nlation-based  evidence  by  describing  metastatic  disease  \noutcomes for treatment-defined subgroups; and includes \nlong-term  data  to  report  outcome",
    "pageHint": 1,
    "needsManualReview": false
  },
  {
    "sourceRefId": "ref-002",
    "filename": "Lord_et_ al.pdf",
    "site": "bone",
    "metricName": null,
    "value": 10,
    "unit": null,
    "notes": "8 10\n These findings \nraise  the  hypothesis  that  adjuvant  therapies  may  delay  \nor prevent bone metastases, or control BC subtypes that \nspread to bone, but have less impact on more aggressive \n",
    "pageHint": 1,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-002",
    "filename": "Lord_et_ al.pdf",
    "site": "metastatic site",
    "metricName": null,
    "value": 11,
    "unit": null,
    "notes": "11\n  It  is  unknown  whether  newer  treat-\nments have altered these patterns of metastatic sites",
    "pageHint": 1,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-002",
    "filename": "Lord_et_ al.pdf",
    "site": "metastases",
    "metricName": null,
    "value": null,
    "unit": "year",
    "notes": "Unfavourable \npattern of metastases in M0 breast cancer patients during 1978-\n2008: a population-based analysis of the munich cancer registry",
    "pageHint": 9,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-002",
    "filename": "Lord_et_ al.pdf",
    "site": "metastases",
    "metricName": null,
    "value": null,
    "unit": "year",
    "notes": "Unfavourable \npattern of metastases in M0 breast cancer patients during 1978-\n2008: a population-based analysis of the munich cancer registry",
    "pageHint": 9,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-002",
    "filename": "Lord_et_ al.pdf",
    "site": "metastases",
    "metricName": null,
    "value": 1978,
    "unit": null,
    "notes": "Unfavourable \npattern of metastases in M0 breast cancer patients during 1978-\n2008: a population-based analysis of the munich cancer registry",
    "pageHint": 9,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-002",
    "filename": "Lord_et_ al.pdf",
    "site": "metastases",
    "metricName": null,
    "value": 2008,
    "unit": null,
    "notes": "Unfavourable \npattern of metastases in M0 breast cancer patients during 1978-\n2008: a population-based analysis of the munich cancer registry",
    "pageHint": 9,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "site": "brain",
    "metricName": null,
    "value": 95,
    "unit": "%",
    "notes": "Analyses predict a decrease in metastases to\nliver (APC=−3.40, 95% CI [−3.50,−3.30]), lung (APC (2019–2030)=−1.90, 95% CI\n[−2.90,−1.00]); (2030–2040)=−3.70, 95% CI [−4.60,−2.80]), bone (APC=−4.00,\n95%",
    "pageHint": 1,
    "needsManualReview": false
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "site": "brain",
    "metricName": null,
    "value": 95,
    "unit": "%",
    "notes": "Analyses predict a decrease in metastases to\nliver (APC=−3.40, 95% CI [−3.50,−3.30]), lung (APC (2019–2030)=−1.90, 95% CI\n[−2.90,−1.00]); (2030–2040)=−3.70, 95% CI [−4.60,−2.80]), bone (APC=−4.00,\n95%",
    "pageHint": 1,
    "needsManualReview": false
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "site": "brain",
    "metricName": null,
    "value": 95,
    "unit": "%",
    "notes": "Analyses predict a decrease in metastases to\nliver (APC=−3.40, 95% CI [−3.50,−3.30]), lung (APC (2019–2030)=−1.90, 95% CI\n[−2.90,−1.00]); (2030–2040)=−3.70, 95% CI [−4.60,−2.80]), bone (APC=−4.00,\n95%",
    "pageHint": 1,
    "needsManualReview": false
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "site": "brain",
    "metricName": null,
    "value": 95,
    "unit": "%",
    "notes": "Analyses predict a decrease in metastases to\nliver (APC=−3.40, 95% CI [−3.50,−3.30]), lung (APC (2019–2030)=−1.90, 95% CI\n[−2.90,−1.00]); (2030–2040)=−3.70, 95% CI [−4.60,−2.80]), bone (APC=−4.00,\n95%",
    "pageHint": 1,
    "needsManualReview": false
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "site": "brain",
    "metricName": null,
    "value": 95,
    "unit": "%",
    "notes": "Analyses predict a decrease in metastases to\nliver (APC=−3.40, 95% CI [−3.50,−3.30]), lung (APC (2019–2030)=−1.90, 95% CI\n[−2.90,−1.00]); (2030–2040)=−3.70, 95% CI [−4.60,−2.80]), bone (APC=−4.00,\n95%",
    "pageHint": 1,
    "needsManualReview": false
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "site": "brain",
    "metricName": null,
    "value": null,
    "unit": "year",
    "notes": "Analyses predict a decrease in metastases to\nliver (APC=−3.40, 95% CI [−3.50,−3.30]), lung (APC (2019–2030)=−1.90, 95% CI\n[−2.90,−1.00]); (2030–2040)=−3.70, 95% CI [−4.60,−2.80]), bone (APC=−4.00,\n95%",
    "pageHint": 1,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "site": "brain",
    "metricName": null,
    "value": null,
    "unit": "year",
    "notes": "Analyses predict a decrease in metastases to\nliver (APC=−3.40, 95% CI [−3.50,−3.30]), lung (APC (2019–2030)=−1.90, 95% CI\n[−2.90,−1.00]); (2030–2040)=−3.70, 95% CI [−4.60,−2.80]), bone (APC=−4.00,\n95%",
    "pageHint": 1,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "site": "brain",
    "metricName": null,
    "value": null,
    "unit": "year",
    "notes": "Analyses predict a decrease in metastases to\nliver (APC=−3.40, 95% CI [−3.50,−3.30]), lung (APC (2019–2030)=−1.90, 95% CI\n[−2.90,−1.00]); (2030–2040)=−3.70, 95% CI [−4.60,−2.80]), bone (APC=−4.00,\n95%",
    "pageHint": 1,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "site": "brain",
    "metricName": null,
    "value": null,
    "unit": "year",
    "notes": "Analyses predict a decrease in metastases to\nliver (APC=−3.40, 95% CI [−3.50,−3.30]), lung (APC (2019–2030)=−1.90, 95% CI\n[−2.90,−1.00]); (2030–2040)=−3.70, 95% CI [−4.60,−2.80]), bone (APC=−4.00,\n95%",
    "pageHint": 1,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "site": "brain",
    "metricName": null,
    "value": 3.4,
    "unit": "%",
    "notes": "Analyses predict a decrease in metastases to\nliver (APC=−3.40, 95% CI [−3.50,−3.30]), lung (APC (2019–2030)=−1.90, 95% CI\n[−2.90,−1.00]); (2030–2040)=−3.70, 95% CI [−4.60,−2.80]), bone (APC=−4.00,\n95%",
    "pageHint": 1,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "site": "brain",
    "metricName": null,
    "value": 3.5,
    "unit": "%",
    "notes": "Analyses predict a decrease in metastases to\nliver (APC=−3.40, 95% CI [−3.50,−3.30]), lung (APC (2019–2030)=−1.90, 95% CI\n[−2.90,−1.00]); (2030–2040)=−3.70, 95% CI [−4.60,−2.80]), bone (APC=−4.00,\n95%",
    "pageHint": 1,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "site": "brain",
    "metricName": null,
    "value": 3.3,
    "unit": "%",
    "notes": "Analyses predict a decrease in metastases to\nliver (APC=−3.40, 95% CI [−3.50,−3.30]), lung (APC (2019–2030)=−1.90, 95% CI\n[−2.90,−1.00]); (2030–2040)=−3.70, 95% CI [−4.60,−2.80]), bone (APC=−4.00,\n95%",
    "pageHint": 1,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "site": "brain",
    "metricName": null,
    "value": 1.9,
    "unit": "%",
    "notes": "Analyses predict a decrease in metastases to\nliver (APC=−3.40, 95% CI [−3.50,−3.30]), lung (APC (2019–2030)=−1.90, 95% CI\n[−2.90,−1.00]); (2030–2040)=−3.70, 95% CI [−4.60,−2.80]), bone (APC=−4.00,\n95%",
    "pageHint": 1,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "site": "brain",
    "metricName": null,
    "value": 2.9,
    "unit": "%",
    "notes": "Analyses predict a decrease in metastases to\nliver (APC=−3.40, 95% CI [−3.50,−3.30]), lung (APC (2019–2030)=−1.90, 95% CI\n[−2.90,−1.00]); (2030–2040)=−3.70, 95% CI [−4.60,−2.80]), bone (APC=−4.00,\n95%",
    "pageHint": 1,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "site": "brain",
    "metricName": null,
    "value": 1,
    "unit": "%",
    "notes": "Analyses predict a decrease in metastases to\nliver (APC=−3.40, 95% CI [−3.50,−3.30]), lung (APC (2019–2030)=−1.90, 95% CI\n[−2.90,−1.00]); (2030–2040)=−3.70, 95% CI [−4.60,−2.80]), bone (APC=−4.00,\n95%",
    "pageHint": 1,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "site": "brain",
    "metricName": null,
    "value": 3.7,
    "unit": "%",
    "notes": "Analyses predict a decrease in metastases to\nliver (APC=−3.40, 95% CI [−3.50,−3.30]), lung (APC (2019–2030)=−1.90, 95% CI\n[−2.90,−1.00]); (2030–2040)=−3.70, 95% CI [−4.60,−2.80]), bone (APC=−4.00,\n95%",
    "pageHint": 1,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "site": "brain",
    "metricName": null,
    "value": 4.6,
    "unit": "%",
    "notes": "Analyses predict a decrease in metastases to\nliver (APC=−3.40, 95% CI [−3.50,−3.30]), lung (APC (2019–2030)=−1.90, 95% CI\n[−2.90,−1.00]); (2030–2040)=−3.70, 95% CI [−4.60,−2.80]), bone (APC=−4.00,\n95%",
    "pageHint": 1,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "site": "brain",
    "metricName": null,
    "value": 2.8,
    "unit": "%",
    "notes": "Analyses predict a decrease in metastases to\nliver (APC=−3.40, 95% CI [−3.50,−3.30]), lung (APC (2019–2030)=−1.90, 95% CI\n[−2.90,−1.00]); (2030–2040)=−3.70, 95% CI [−4.60,−2.80]), bone (APC=−4.00,\n95%",
    "pageHint": 1,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "site": "brain",
    "metricName": null,
    "value": 4,
    "unit": "%",
    "notes": "Analyses predict a decrease in metastases to\nliver (APC=−3.40, 95% CI [−3.50,−3.30]), lung (APC (2019–2030)=−1.90, 95% CI\n[−2.90,−1.00]); (2030–2040)=−3.70, 95% CI [−4.60,−2.80]), bone (APC=−4.00,\n95%",
    "pageHint": 1,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "site": "brain",
    "metricName": null,
    "value": 4.3,
    "unit": "%",
    "notes": "Analyses predict a decrease in metastases to\nliver (APC=−3.40, 95% CI [−3.50,−3.30]), lung (APC (2019–2030)=−1.90, 95% CI\n[−2.90,−1.00]); (2030–2040)=−3.70, 95% CI [−4.60,−2.80]), bone (APC=−4.00,\n95%",
    "pageHint": 1,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "site": "brain",
    "metricName": null,
    "value": 3.7,
    "unit": "%",
    "notes": "Analyses predict a decrease in metastases to\nliver (APC=−3.40, 95% CI [−3.50,−3.30]), lung (APC (2019–2030)=−1.90, 95% CI\n[−2.90,−1.00]); (2030–2040)=−3.70, 95% CI [−4.60,−2.80]), bone (APC=−4.00,\n95%",
    "pageHint": 1,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "site": "brain",
    "metricName": null,
    "value": 2.3,
    "unit": "%",
    "notes": "Analyses predict a decrease in metastases to\nliver (APC=−3.40, 95% CI [−3.50,−3.30]), lung (APC (2019–2030)=−1.90, 95% CI\n[−2.90,−1.00]); (2030–2040)=−3.70, 95% CI [−4.60,−2.80]), bone (APC=−4.00,\n95%",
    "pageHint": 1,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "site": "brain",
    "metricName": null,
    "value": 2.6,
    "unit": "%",
    "notes": "Analyses predict a decrease in metastases to\nliver (APC=−3.40, 95% CI [−3.50,−3.30]), lung (APC (2019–2030)=−1.90, 95% CI\n[−2.90,−1.00]); (2030–2040)=−3.70, 95% CI [−4.60,−2.80]), bone (APC=−4.00,\n95%",
    "pageHint": 1,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "site": "brain",
    "metricName": null,
    "value": 2,
    "unit": "%",
    "notes": "Analyses predict a decrease in metastases to\nliver (APC=−3.40, 95% CI [−3.50,−3.30]), lung (APC (2019–2030)=−1.90, 95% CI\n[−2.90,−1.00]); (2030–2040)=−3.70, 95% CI [−4.60,−2.80]), bone (APC=−4.00,\n95%",
    "pageHint": 1,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "site": "brain",
    "metricName": null,
    "value": 40,
    "unit": "%",
    "notes": "Analyses predict a decrease in metastases to\nliver (APC=−3.40, 95% CI [−3.50,−3.30]), lung (APC (2019–2030)=−1.90, 95% CI\n[−2.90,−1.00]); (2030–2040)=−3.70, 95% CI [−4.60,−2.80]), bone (APC=−4.00,\n95%",
    "pageHint": 1,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "site": "brain",
    "metricName": null,
    "value": 95,
    "unit": "%",
    "notes": "Analyses predict a decrease in metastases to\nliver (APC=−3.40, 95% CI [−3.50,−3.30]), lung (APC (2019–2030)=−1.90, 95% CI\n[−2.90,−1.00]); (2030–2040)=−3.70, 95% CI [−4.60,−2.80]), bone (APC=−4.00,\n95%",
    "pageHint": 1,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "site": "brain",
    "metricName": null,
    "value": 50,
    "unit": "%",
    "notes": "Analyses predict a decrease in metastases to\nliver (APC=−3.40, 95% CI [−3.50,−3.30]), lung (APC (2019–2030)=−1.90, 95% CI\n[−2.90,−1.00]); (2030–2040)=−3.70, 95% CI [−4.60,−2.80]), bone (APC=−4.00,\n95%",
    "pageHint": 1,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "site": "brain",
    "metricName": null,
    "value": 30,
    "unit": "%",
    "notes": "Analyses predict a decrease in metastases to\nliver (APC=−3.40, 95% CI [−3.50,−3.30]), lung (APC (2019–2030)=−1.90, 95% CI\n[−2.90,−1.00]); (2030–2040)=−3.70, 95% CI [−4.60,−2.80]), bone (APC=−4.00,\n95%",
    "pageHint": 1,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "site": "brain",
    "metricName": null,
    "value": 2019,
    "unit": "%",
    "notes": "Analyses predict a decrease in metastases to\nliver (APC=−3.40, 95% CI [−3.50,−3.30]), lung (APC (2019–2030)=−1.90, 95% CI\n[−2.90,−1.00]); (2030–2040)=−3.70, 95% CI [−4.60,−2.80]), bone (APC=−4.00,\n95%",
    "pageHint": 1,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "site": "brain",
    "metricName": null,
    "value": 2030,
    "unit": "%",
    "notes": "Analyses predict a decrease in metastases to\nliver (APC=−3.40, 95% CI [−3.50,−3.30]), lung (APC (2019–2030)=−1.90, 95% CI\n[−2.90,−1.00]); (2030–2040)=−3.70, 95% CI [−4.60,−2.80]), bone (APC=−4.00,\n95%",
    "pageHint": 1,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "site": "brain",
    "metricName": null,
    "value": 90,
    "unit": "%",
    "notes": "Analyses predict a decrease in metastases to\nliver (APC=−3.40, 95% CI [−3.50,−3.30]), lung (APC (2019–2030)=−1.90, 95% CI\n[−2.90,−1.00]); (2030–2040)=−3.70, 95% CI [−4.60,−2.80]), bone (APC=−4.00,\n95%",
    "pageHint": 1,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "site": "brain",
    "metricName": null,
    "value": 95,
    "unit": "%",
    "notes": "Analyses predict a decrease in metastases to\nliver (APC=−3.40, 95% CI [−3.50,−3.30]), lung (APC (2019–2030)=−1.90, 95% CI\n[−2.90,−1.00]); (2030–2040)=−3.70, 95% CI [−4.60,−2.80]), bone (APC=−4.00,\n95%",
    "pageHint": 1,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "site": "brain",
    "metricName": null,
    "value": 90,
    "unit": "%",
    "notes": "Analyses predict a decrease in metastases to\nliver (APC=−3.40, 95% CI [−3.50,−3.30]), lung (APC (2019–2030)=−1.90, 95% CI\n[−2.90,−1.00]); (2030–2040)=−3.70, 95% CI [−4.60,−2.80]), bone (APC=−4.00,\n95%",
    "pageHint": 1,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "site": "brain",
    "metricName": null,
    "value": 0,
    "unit": "%",
    "notes": "Analyses predict a decrease in metastases to\nliver (APC=−3.40, 95% CI [−3.50,−3.30]), lung (APC (2019–2030)=−1.90, 95% CI\n[−2.90,−1.00]); (2030–2040)=−3.70, 95% CI [−4.60,−2.80]), bone (APC=−4.00,\n95%",
    "pageHint": 1,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "site": "brain",
    "metricName": null,
    "value": 2030,
    "unit": "%",
    "notes": "Analyses predict a decrease in metastases to\nliver (APC=−3.40, 95% CI [−3.50,−3.30]), lung (APC (2019–2030)=−1.90, 95% CI\n[−2.90,−1.00]); (2030–2040)=−3.70, 95% CI [−4.60,−2.80]), bone (APC=−4.00,\n95%",
    "pageHint": 1,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "site": "brain",
    "metricName": null,
    "value": 2040,
    "unit": "%",
    "notes": "Analyses predict a decrease in metastases to\nliver (APC=−3.40, 95% CI [−3.50,−3.30]), lung (APC (2019–2030)=−1.90, 95% CI\n[−2.90,−1.00]); (2030–2040)=−3.70, 95% CI [−4.60,−2.80]), bone (APC=−4.00,\n95%",
    "pageHint": 1,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "site": "brain",
    "metricName": null,
    "value": 70,
    "unit": "%",
    "notes": "Analyses predict a decrease in metastases to\nliver (APC=−3.40, 95% CI [−3.50,−3.30]), lung (APC (2019–2030)=−1.90, 95% CI\n[−2.90,−1.00]); (2030–2040)=−3.70, 95% CI [−4.60,−2.80]), bone (APC=−4.00,\n95%",
    "pageHint": 1,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "site": "brain",
    "metricName": null,
    "value": 95,
    "unit": "%",
    "notes": "Analyses predict a decrease in metastases to\nliver (APC=−3.40, 95% CI [−3.50,−3.30]), lung (APC (2019–2030)=−1.90, 95% CI\n[−2.90,−1.00]); (2030–2040)=−3.70, 95% CI [−4.60,−2.80]), bone (APC=−4.00,\n95%",
    "pageHint": 1,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "site": "brain",
    "metricName": null,
    "value": 60,
    "unit": "%",
    "notes": "Analyses predict a decrease in metastases to\nliver (APC=−3.40, 95% CI [−3.50,−3.30]), lung (APC (2019–2030)=−1.90, 95% CI\n[−2.90,−1.00]); (2030–2040)=−3.70, 95% CI [−4.60,−2.80]), bone (APC=−4.00,\n95%",
    "pageHint": 1,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "site": "brain",
    "metricName": null,
    "value": 80,
    "unit": "%",
    "notes": "Analyses predict a decrease in metastases to\nliver (APC=−3.40, 95% CI [−3.50,−3.30]), lung (APC (2019–2030)=−1.90, 95% CI\n[−2.90,−1.00]); (2030–2040)=−3.70, 95% CI [−4.60,−2.80]), bone (APC=−4.00,\n95%",
    "pageHint": 1,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "site": "brain",
    "metricName": null,
    "value": 0,
    "unit": "%",
    "notes": "Analyses predict a decrease in metastases to\nliver (APC=−3.40, 95% CI [−3.50,−3.30]), lung (APC (2019–2030)=−1.90, 95% CI\n[−2.90,−1.00]); (2030–2040)=−3.70, 95% CI [−4.60,−2.80]), bone (APC=−4.00,\n95%",
    "pageHint": 1,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "site": "brain",
    "metricName": null,
    "value": 95,
    "unit": "%",
    "notes": "Analyses predict a decrease in metastases to\nliver (APC=−3.40, 95% CI [−3.50,−3.30]), lung (APC (2019–2030)=−1.90, 95% CI\n[−2.90,−1.00]); (2030–2040)=−3.70, 95% CI [−4.60,−2.80]), bone (APC=−4.00,\n95%",
    "pageHint": 1,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "site": "brain",
    "metricName": null,
    "value": 30,
    "unit": "%",
    "notes": "Analyses predict a decrease in metastases to\nliver (APC=−3.40, 95% CI [−3.50,−3.30]), lung (APC (2019–2030)=−1.90, 95% CI\n[−2.90,−1.00]); (2030–2040)=−3.70, 95% CI [−4.60,−2.80]), bone (APC=−4.00,\n95%",
    "pageHint": 1,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "site": "brain",
    "metricName": null,
    "value": 70,
    "unit": "%",
    "notes": "Analyses predict a decrease in metastases to\nliver (APC=−3.40, 95% CI [−3.50,−3.30]), lung (APC (2019–2030)=−1.90, 95% CI\n[−2.90,−1.00]); (2030–2040)=−3.70, 95% CI [−4.60,−2.80]), bone (APC=−4.00,\n95%",
    "pageHint": 1,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "site": "brain",
    "metricName": null,
    "value": 30,
    "unit": "%",
    "notes": "Analyses predict a decrease in metastases to\nliver (APC=−3.40, 95% CI [−3.50,−3.30]), lung (APC (2019–2030)=−1.90, 95% CI\n[−2.90,−1.00]); (2030–2040)=−3.70, 95% CI [−4.60,−2.80]), bone (APC=−4.00,\n95%",
    "pageHint": 1,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "site": "brain",
    "metricName": null,
    "value": 95,
    "unit": "%",
    "notes": "Analyses predict a decrease in metastases to\nliver (APC=−3.40, 95% CI [−3.50,−3.30]), lung (APC (2019–2030)=−1.90, 95% CI\n[−2.90,−1.00]); (2030–2040)=−3.70, 95% CI [−4.60,−2.80]), bone (APC=−4.00,\n95%",
    "pageHint": 1,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "site": "brain",
    "metricName": null,
    "value": 60,
    "unit": "%",
    "notes": "Analyses predict a decrease in metastases to\nliver (APC=−3.40, 95% CI [−3.50,−3.30]), lung (APC (2019–2030)=−1.90, 95% CI\n[−2.90,−1.00]); (2030–2040)=−3.70, 95% CI [−4.60,−2.80]), bone (APC=−4.00,\n95%",
    "pageHint": 1,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "site": "brain",
    "metricName": null,
    "value": 0,
    "unit": "%",
    "notes": "Analyses predict a decrease in metastases to\nliver (APC=−3.40, 95% CI [−3.50,−3.30]), lung (APC (2019–2030)=−1.90, 95% CI\n[−2.90,−1.00]); (2030–2040)=−3.70, 95% CI [−4.60,−2.80]), bone (APC=−4.00,\n95%",
    "pageHint": 1,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "site": "brain",
    "metricName": null,
    "value": 95,
    "unit": "%",
    "notes": "Our analyses predict a\ndecrease in metastases to lung ((APC (2019–2030)=−1.90, 95%\nCI [−2.90,−1.00];p< 0.001), (2030–2040)=−3.70, 95% CI\n[−4.60,−2.80];p< 0.001)), liver (APC=−3.40, 95% CI [−3.50,\n−3.3",
    "pageHint": 2,
    "needsManualReview": false
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "site": "brain",
    "metricName": null,
    "value": 95,
    "unit": "%",
    "notes": "Our analyses predict a\ndecrease in metastases to lung ((APC (2019–2030)=−1.90, 95%\nCI [−2.90,−1.00];p< 0.001), (2030–2040)=−3.70, 95% CI\n[−4.60,−2.80];p< 0.001)), liver (APC=−3.40, 95% CI [−3.50,\n−3.3",
    "pageHint": 2,
    "needsManualReview": false
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "site": "brain",
    "metricName": null,
    "value": 95,
    "unit": "%",
    "notes": "Our analyses predict a\ndecrease in metastases to lung ((APC (2019–2030)=−1.90, 95%\nCI [−2.90,−1.00];p< 0.001), (2030–2040)=−3.70, 95% CI\n[−4.60,−2.80];p< 0.001)), liver (APC=−3.40, 95% CI [−3.50,\n−3.3",
    "pageHint": 2,
    "needsManualReview": false
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "site": "brain",
    "metricName": null,
    "value": 95,
    "unit": "%",
    "notes": "Our analyses predict a\ndecrease in metastases to lung ((APC (2019–2030)=−1.90, 95%\nCI [−2.90,−1.00];p< 0.001), (2030–2040)=−3.70, 95% CI\n[−4.60,−2.80];p< 0.001)), liver (APC=−3.40, 95% CI [−3.50,\n−3.3",
    "pageHint": 2,
    "needsManualReview": false
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "site": "brain",
    "metricName": null,
    "value": 95,
    "unit": "%",
    "notes": "Our analyses predict a\ndecrease in metastases to lung ((APC (2019–2030)=−1.90, 95%\nCI [−2.90,−1.00];p< 0.001), (2030–2040)=−3.70, 95% CI\n[−4.60,−2.80];p< 0.001)), liver (APC=−3.40, 95% CI [−3.50,\n−3.3",
    "pageHint": 2,
    "needsManualReview": false
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "site": "brain",
    "metricName": null,
    "value": null,
    "unit": "year",
    "notes": "Our analyses predict a\ndecrease in metastases to lung ((APC (2019–2030)=−1.90, 95%\nCI [−2.90,−1.00];p< 0.001), (2030–2040)=−3.70, 95% CI\n[−4.60,−2.80];p< 0.001)), liver (APC=−3.40, 95% CI [−3.50,\n−3.3",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "site": "brain",
    "metricName": null,
    "value": null,
    "unit": "year",
    "notes": "Our analyses predict a\ndecrease in metastases to lung ((APC (2019–2030)=−1.90, 95%\nCI [−2.90,−1.00];p< 0.001), (2030–2040)=−3.70, 95% CI\n[−4.60,−2.80];p< 0.001)), liver (APC=−3.40, 95% CI [−3.50,\n−3.3",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "site": "brain",
    "metricName": null,
    "value": null,
    "unit": "year",
    "notes": "Our analyses predict a\ndecrease in metastases to lung ((APC (2019–2030)=−1.90, 95%\nCI [−2.90,−1.00];p< 0.001), (2030–2040)=−3.70, 95% CI\n[−4.60,−2.80];p< 0.001)), liver (APC=−3.40, 95% CI [−3.50,\n−3.3",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "site": "brain",
    "metricName": null,
    "value": null,
    "unit": "year",
    "notes": "Our analyses predict a\ndecrease in metastases to lung ((APC (2019–2030)=−1.90, 95%\nCI [−2.90,−1.00];p< 0.001), (2030–2040)=−3.70, 95% CI\n[−4.60,−2.80];p< 0.001)), liver (APC=−3.40, 95% CI [−3.50,\n−3.3",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "site": "brain",
    "metricName": null,
    "value": null,
    "unit": "year",
    "notes": "Our analyses predict a\ndecrease in metastases to lung ((APC (2019–2030)=−1.90, 95%\nCI [−2.90,−1.00];p< 0.001), (2030–2040)=−3.70, 95% CI\n[−4.60,−2.80];p< 0.001)), liver (APC=−3.40, 95% CI [−3.50,\n−3.3",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "site": "brain",
    "metricName": null,
    "value": 1.9,
    "unit": "%",
    "notes": "Our analyses predict a\ndecrease in metastases to lung ((APC (2019–2030)=−1.90, 95%\nCI [−2.90,−1.00];p< 0.001), (2030–2040)=−3.70, 95% CI\n[−4.60,−2.80];p< 0.001)), liver (APC=−3.40, 95% CI [−3.50,\n−3.3",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "site": "brain",
    "metricName": null,
    "value": 2.9,
    "unit": "%",
    "notes": "Our analyses predict a\ndecrease in metastases to lung ((APC (2019–2030)=−1.90, 95%\nCI [−2.90,−1.00];p< 0.001), (2030–2040)=−3.70, 95% CI\n[−4.60,−2.80];p< 0.001)), liver (APC=−3.40, 95% CI [−3.50,\n−3.3",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "site": "brain",
    "metricName": null,
    "value": 1,
    "unit": "%",
    "notes": "Our analyses predict a\ndecrease in metastases to lung ((APC (2019–2030)=−1.90, 95%\nCI [−2.90,−1.00];p< 0.001), (2030–2040)=−3.70, 95% CI\n[−4.60,−2.80];p< 0.001)), liver (APC=−3.40, 95% CI [−3.50,\n−3.3",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "site": "brain",
    "metricName": null,
    "value": 0.001,
    "unit": "%",
    "notes": "Our analyses predict a\ndecrease in metastases to lung ((APC (2019–2030)=−1.90, 95%\nCI [−2.90,−1.00];p< 0.001), (2030–2040)=−3.70, 95% CI\n[−4.60,−2.80];p< 0.001)), liver (APC=−3.40, 95% CI [−3.50,\n−3.3",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "site": "brain",
    "metricName": null,
    "value": 3.7,
    "unit": "%",
    "notes": "Our analyses predict a\ndecrease in metastases to lung ((APC (2019–2030)=−1.90, 95%\nCI [−2.90,−1.00];p< 0.001), (2030–2040)=−3.70, 95% CI\n[−4.60,−2.80];p< 0.001)), liver (APC=−3.40, 95% CI [−3.50,\n−3.3",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "site": "brain",
    "metricName": null,
    "value": 4.6,
    "unit": "%",
    "notes": "Our analyses predict a\ndecrease in metastases to lung ((APC (2019–2030)=−1.90, 95%\nCI [−2.90,−1.00];p< 0.001), (2030–2040)=−3.70, 95% CI\n[−4.60,−2.80];p< 0.001)), liver (APC=−3.40, 95% CI [−3.50,\n−3.3",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "site": "brain",
    "metricName": null,
    "value": 2.8,
    "unit": "%",
    "notes": "Our analyses predict a\ndecrease in metastases to lung ((APC (2019–2030)=−1.90, 95%\nCI [−2.90,−1.00];p< 0.001), (2030–2040)=−3.70, 95% CI\n[−4.60,−2.80];p< 0.001)), liver (APC=−3.40, 95% CI [−3.50,\n−3.3",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "site": "brain",
    "metricName": null,
    "value": 0.001,
    "unit": "%",
    "notes": "Our analyses predict a\ndecrease in metastases to lung ((APC (2019–2030)=−1.90, 95%\nCI [−2.90,−1.00];p< 0.001), (2030–2040)=−3.70, 95% CI\n[−4.60,−2.80];p< 0.001)), liver (APC=−3.40, 95% CI [−3.50,\n−3.3",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "site": "brain",
    "metricName": null,
    "value": 3.4,
    "unit": "%",
    "notes": "Our analyses predict a\ndecrease in metastases to lung ((APC (2019–2030)=−1.90, 95%\nCI [−2.90,−1.00];p< 0.001), (2030–2040)=−3.70, 95% CI\n[−4.60,−2.80];p< 0.001)), liver (APC=−3.40, 95% CI [−3.50,\n−3.3",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "site": "brain",
    "metricName": null,
    "value": 3.5,
    "unit": "%",
    "notes": "Our analyses predict a\ndecrease in metastases to lung ((APC (2019–2030)=−1.90, 95%\nCI [−2.90,−1.00];p< 0.001), (2030–2040)=−3.70, 95% CI\n[−4.60,−2.80];p< 0.001)), liver (APC=−3.40, 95% CI [−3.50,\n−3.3",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "site": "brain",
    "metricName": null,
    "value": 3.3,
    "unit": "%",
    "notes": "Our analyses predict a\ndecrease in metastases to lung ((APC (2019–2030)=−1.90, 95%\nCI [−2.90,−1.00];p< 0.001), (2030–2040)=−3.70, 95% CI\n[−4.60,−2.80];p< 0.001)), liver (APC=−3.40, 95% CI [−3.50,\n−3.3",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "site": "brain",
    "metricName": null,
    "value": 0.001,
    "unit": "%",
    "notes": "Our analyses predict a\ndecrease in metastases to lung ((APC (2019–2030)=−1.90, 95%\nCI [−2.90,−1.00];p< 0.001), (2030–2040)=−3.70, 95% CI\n[−4.60,−2.80];p< 0.001)), liver (APC=−3.40, 95% CI [−3.50,\n−3.3",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "site": "brain",
    "metricName": null,
    "value": 4,
    "unit": "%",
    "notes": "Our analyses predict a\ndecrease in metastases to lung ((APC (2019–2030)=−1.90, 95%\nCI [−2.90,−1.00];p< 0.001), (2030–2040)=−3.70, 95% CI\n[−4.60,−2.80];p< 0.001)), liver (APC=−3.40, 95% CI [−3.50,\n−3.3",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "site": "brain",
    "metricName": null,
    "value": 4.3,
    "unit": "%",
    "notes": "Our analyses predict a\ndecrease in metastases to lung ((APC (2019–2030)=−1.90, 95%\nCI [−2.90,−1.00];p< 0.001), (2030–2040)=−3.70, 95% CI\n[−4.60,−2.80];p< 0.001)), liver (APC=−3.40, 95% CI [−3.50,\n−3.3",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "site": "brain",
    "metricName": null,
    "value": 3.7,
    "unit": "%",
    "notes": "Our analyses predict a\ndecrease in metastases to lung ((APC (2019–2030)=−1.90, 95%\nCI [−2.90,−1.00];p< 0.001), (2030–2040)=−3.70, 95% CI\n[−4.60,−2.80];p< 0.001)), liver (APC=−3.40, 95% CI [−3.50,\n−3.3",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "site": "brain",
    "metricName": null,
    "value": 0.001,
    "unit": "%",
    "notes": "Our analyses predict a\ndecrease in metastases to lung ((APC (2019–2030)=−1.90, 95%\nCI [−2.90,−1.00];p< 0.001), (2030–2040)=−3.70, 95% CI\n[−4.60,−2.80];p< 0.001)), liver (APC=−3.40, 95% CI [−3.50,\n−3.3",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "site": "brain",
    "metricName": null,
    "value": 2.3,
    "unit": "%",
    "notes": "Our analyses predict a\ndecrease in metastases to lung ((APC (2019–2030)=−1.90, 95%\nCI [−2.90,−1.00];p< 0.001), (2030–2040)=−3.70, 95% CI\n[−4.60,−2.80];p< 0.001)), liver (APC=−3.40, 95% CI [−3.50,\n−3.3",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "site": "brain",
    "metricName": null,
    "value": 2.6,
    "unit": "%",
    "notes": "Our analyses predict a\ndecrease in metastases to lung ((APC (2019–2030)=−1.90, 95%\nCI [−2.90,−1.00];p< 0.001), (2030–2040)=−3.70, 95% CI\n[−4.60,−2.80];p< 0.001)), liver (APC=−3.40, 95% CI [−3.50,\n−3.3",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "site": "brain",
    "metricName": null,
    "value": 2,
    "unit": "%",
    "notes": "Our analyses predict a\ndecrease in metastases to lung ((APC (2019–2030)=−1.90, 95%\nCI [−2.90,−1.00];p< 0.001), (2030–2040)=−3.70, 95% CI\n[−4.60,−2.80];p< 0.001)), liver (APC=−3.40, 95% CI [−3.50,\n−3.3",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "site": "brain",
    "metricName": null,
    "value": 0.001,
    "unit": "%",
    "notes": "Our analyses predict a\ndecrease in metastases to lung ((APC (2019–2030)=−1.90, 95%\nCI [−2.90,−1.00];p< 0.001), (2030–2040)=−3.70, 95% CI\n[−4.60,−2.80];p< 0.001)), liver (APC=−3.40, 95% CI [−3.50,\n−3.3",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "site": "brain",
    "metricName": null,
    "value": 2019,
    "unit": "%",
    "notes": "Our analyses predict a\ndecrease in metastases to lung ((APC (2019–2030)=−1.90, 95%\nCI [−2.90,−1.00];p< 0.001), (2030–2040)=−3.70, 95% CI\n[−4.60,−2.80];p< 0.001)), liver (APC=−3.40, 95% CI [−3.50,\n−3.3",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "site": "brain",
    "metricName": null,
    "value": 2030,
    "unit": "%",
    "notes": "Our analyses predict a\ndecrease in metastases to lung ((APC (2019–2030)=−1.90, 95%\nCI [−2.90,−1.00];p< 0.001), (2030–2040)=−3.70, 95% CI\n[−4.60,−2.80];p< 0.001)), liver (APC=−3.40, 95% CI [−3.50,\n−3.3",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "site": "brain",
    "metricName": null,
    "value": 90,
    "unit": "%",
    "notes": "Our analyses predict a\ndecrease in metastases to lung ((APC (2019–2030)=−1.90, 95%\nCI [−2.90,−1.00];p< 0.001), (2030–2040)=−3.70, 95% CI\n[−4.60,−2.80];p< 0.001)), liver (APC=−3.40, 95% CI [−3.50,\n−3.3",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "site": "brain",
    "metricName": null,
    "value": 95,
    "unit": "%",
    "notes": "Our analyses predict a\ndecrease in metastases to lung ((APC (2019–2030)=−1.90, 95%\nCI [−2.90,−1.00];p< 0.001), (2030–2040)=−3.70, 95% CI\n[−4.60,−2.80];p< 0.001)), liver (APC=−3.40, 95% CI [−3.50,\n−3.3",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "site": "brain",
    "metricName": null,
    "value": 90,
    "unit": "%",
    "notes": "Our analyses predict a\ndecrease in metastases to lung ((APC (2019–2030)=−1.90, 95%\nCI [−2.90,−1.00];p< 0.001), (2030–2040)=−3.70, 95% CI\n[−4.60,−2.80];p< 0.001)), liver (APC=−3.40, 95% CI [−3.50,\n−3.3",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "site": "brain",
    "metricName": null,
    "value": 0,
    "unit": "%",
    "notes": "Our analyses predict a\ndecrease in metastases to lung ((APC (2019–2030)=−1.90, 95%\nCI [−2.90,−1.00];p< 0.001), (2030–2040)=−3.70, 95% CI\n[−4.60,−2.80];p< 0.001)), liver (APC=−3.40, 95% CI [−3.50,\n−3.3",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "site": "brain",
    "metricName": null,
    "value": 1,
    "unit": "%",
    "notes": "Our analyses predict a\ndecrease in metastases to lung ((APC (2019–2030)=−1.90, 95%\nCI [−2.90,−1.00];p< 0.001), (2030–2040)=−3.70, 95% CI\n[−4.60,−2.80];p< 0.001)), liver (APC=−3.40, 95% CI [−3.50,\n−3.3",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "site": "brain",
    "metricName": null,
    "value": 2030,
    "unit": "%",
    "notes": "Our analyses predict a\ndecrease in metastases to lung ((APC (2019–2030)=−1.90, 95%\nCI [−2.90,−1.00];p< 0.001), (2030–2040)=−3.70, 95% CI\n[−4.60,−2.80];p< 0.001)), liver (APC=−3.40, 95% CI [−3.50,\n−3.3",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "site": "brain",
    "metricName": null,
    "value": 2040,
    "unit": "%",
    "notes": "Our analyses predict a\ndecrease in metastases to lung ((APC (2019–2030)=−1.90, 95%\nCI [−2.90,−1.00];p< 0.001), (2030–2040)=−3.70, 95% CI\n[−4.60,−2.80];p< 0.001)), liver (APC=−3.40, 95% CI [−3.50,\n−3.3",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "site": "brain",
    "metricName": null,
    "value": 70,
    "unit": "%",
    "notes": "Our analyses predict a\ndecrease in metastases to lung ((APC (2019–2030)=−1.90, 95%\nCI [−2.90,−1.00];p< 0.001), (2030–2040)=−3.70, 95% CI\n[−4.60,−2.80];p< 0.001)), liver (APC=−3.40, 95% CI [−3.50,\n−3.3",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "site": "brain",
    "metricName": null,
    "value": 95,
    "unit": "%",
    "notes": "Our analyses predict a\ndecrease in metastases to lung ((APC (2019–2030)=−1.90, 95%\nCI [−2.90,−1.00];p< 0.001), (2030–2040)=−3.70, 95% CI\n[−4.60,−2.80];p< 0.001)), liver (APC=−3.40, 95% CI [−3.50,\n−3.3",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "site": "brain",
    "metricName": null,
    "value": 60,
    "unit": "%",
    "notes": "Our analyses predict a\ndecrease in metastases to lung ((APC (2019–2030)=−1.90, 95%\nCI [−2.90,−1.00];p< 0.001), (2030–2040)=−3.70, 95% CI\n[−4.60,−2.80];p< 0.001)), liver (APC=−3.40, 95% CI [−3.50,\n−3.3",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "site": "brain",
    "metricName": null,
    "value": 80,
    "unit": "%",
    "notes": "Our analyses predict a\ndecrease in metastases to lung ((APC (2019–2030)=−1.90, 95%\nCI [−2.90,−1.00];p< 0.001), (2030–2040)=−3.70, 95% CI\n[−4.60,−2.80];p< 0.001)), liver (APC=−3.40, 95% CI [−3.50,\n−3.3",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "site": "brain",
    "metricName": null,
    "value": 1,
    "unit": "%",
    "notes": "Our analyses predict a\ndecrease in metastases to lung ((APC (2019–2030)=−1.90, 95%\nCI [−2.90,−1.00];p< 0.001), (2030–2040)=−3.70, 95% CI\n[−4.60,−2.80];p< 0.001)), liver (APC=−3.40, 95% CI [−3.50,\n−3.3",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "site": "brain",
    "metricName": null,
    "value": 40,
    "unit": "%",
    "notes": "Our analyses predict a\ndecrease in metastases to lung ((APC (2019–2030)=−1.90, 95%\nCI [−2.90,−1.00];p< 0.001), (2030–2040)=−3.70, 95% CI\n[−4.60,−2.80];p< 0.001)), liver (APC=−3.40, 95% CI [−3.50,\n−3.3",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "site": "brain",
    "metricName": null,
    "value": 95,
    "unit": "%",
    "notes": "Our analyses predict a\ndecrease in metastases to lung ((APC (2019–2030)=−1.90, 95%\nCI [−2.90,−1.00];p< 0.001), (2030–2040)=−3.70, 95% CI\n[−4.60,−2.80];p< 0.001)), liver (APC=−3.40, 95% CI [−3.50,\n−3.3",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "site": "brain",
    "metricName": null,
    "value": 50,
    "unit": "%",
    "notes": "Our analyses predict a\ndecrease in metastases to lung ((APC (2019–2030)=−1.90, 95%\nCI [−2.90,−1.00];p< 0.001), (2030–2040)=−3.70, 95% CI\n[−4.60,−2.80];p< 0.001)), liver (APC=−3.40, 95% CI [−3.50,\n−3.3",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "site": "brain",
    "metricName": null,
    "value": 30,
    "unit": "%",
    "notes": "Our analyses predict a\ndecrease in metastases to lung ((APC (2019–2030)=−1.90, 95%\nCI [−2.90,−1.00];p< 0.001), (2030–2040)=−3.70, 95% CI\n[−4.60,−2.80];p< 0.001)), liver (APC=−3.40, 95% CI [−3.50,\n−3.3",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "site": "brain",
    "metricName": null,
    "value": 1,
    "unit": "%",
    "notes": "Our analyses predict a\ndecrease in metastases to lung ((APC (2019–2030)=−1.90, 95%\nCI [−2.90,−1.00];p< 0.001), (2030–2040)=−3.70, 95% CI\n[−4.60,−2.80];p< 0.001)), liver (APC=−3.40, 95% CI [−3.50,\n−3.3",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "site": "brain",
    "metricName": null,
    "value": 0,
    "unit": "%",
    "notes": "Our analyses predict a\ndecrease in metastases to lung ((APC (2019–2030)=−1.90, 95%\nCI [−2.90,−1.00];p< 0.001), (2030–2040)=−3.70, 95% CI\n[−4.60,−2.80];p< 0.001)), liver (APC=−3.40, 95% CI [−3.50,\n−3.3",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "site": "brain",
    "metricName": null,
    "value": 95,
    "unit": "%",
    "notes": "Our analyses predict a\ndecrease in metastases to lung ((APC (2019–2030)=−1.90, 95%\nCI [−2.90,−1.00];p< 0.001), (2030–2040)=−3.70, 95% CI\n[−4.60,−2.80];p< 0.001)), liver (APC=−3.40, 95% CI [−3.50,\n−3.3",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "site": "brain",
    "metricName": null,
    "value": 30,
    "unit": "%",
    "notes": "Our analyses predict a\ndecrease in metastases to lung ((APC (2019–2030)=−1.90, 95%\nCI [−2.90,−1.00];p< 0.001), (2030–2040)=−3.70, 95% CI\n[−4.60,−2.80];p< 0.001)), liver (APC=−3.40, 95% CI [−3.50,\n−3.3",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "site": "brain",
    "metricName": null,
    "value": 70,
    "unit": "%",
    "notes": "Our analyses predict a\ndecrease in metastases to lung ((APC (2019–2030)=−1.90, 95%\nCI [−2.90,−1.00];p< 0.001), (2030–2040)=−3.70, 95% CI\n[−4.60,−2.80];p< 0.001)), liver (APC=−3.40, 95% CI [−3.50,\n−3.3",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "site": "brain",
    "metricName": null,
    "value": 1,
    "unit": "%",
    "notes": "Our analyses predict a\ndecrease in metastases to lung ((APC (2019–2030)=−1.90, 95%\nCI [−2.90,−1.00];p< 0.001), (2030–2040)=−3.70, 95% CI\n[−4.60,−2.80];p< 0.001)), liver (APC=−3.40, 95% CI [−3.50,\n−3.3",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "site": "brain",
    "metricName": null,
    "value": 30,
    "unit": "%",
    "notes": "Our analyses predict a\ndecrease in metastases to lung ((APC (2019–2030)=−1.90, 95%\nCI [−2.90,−1.00];p< 0.001), (2030–2040)=−3.70, 95% CI\n[−4.60,−2.80];p< 0.001)), liver (APC=−3.40, 95% CI [−3.50,\n−3.3",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "site": "brain",
    "metricName": null,
    "value": 95,
    "unit": "%",
    "notes": "Our analyses predict a\ndecrease in metastases to lung ((APC (2019–2030)=−1.90, 95%\nCI [−2.90,−1.00];p< 0.001), (2030–2040)=−3.70, 95% CI\n[−4.60,−2.80];p< 0.001)), liver (APC=−3.40, 95% CI [−3.50,\n−3.3",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "site": "brain",
    "metricName": null,
    "value": 60,
    "unit": "%",
    "notes": "Our analyses predict a\ndecrease in metastases to lung ((APC (2019–2030)=−1.90, 95%\nCI [−2.90,−1.00];p< 0.001), (2030–2040)=−3.70, 95% CI\n[−4.60,−2.80];p< 0.001)), liver (APC=−3.40, 95% CI [−3.50,\n−3.3",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "site": "brain",
    "metricName": null,
    "value": 0,
    "unit": "%",
    "notes": "Our analyses predict a\ndecrease in metastases to lung ((APC (2019–2030)=−1.90, 95%\nCI [−2.90,−1.00];p< 0.001), (2030–2040)=−3.70, 95% CI\n[−4.60,−2.80];p< 0.001)), liver (APC=−3.40, 95% CI [−3.50,\n−3.3",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "site": "brain",
    "metricName": null,
    "value": 1,
    "unit": "%",
    "notes": "Our analyses predict a\ndecrease in metastases to lung ((APC (2019–2030)=−1.90, 95%\nCI [−2.90,−1.00];p< 0.001), (2030–2040)=−3.70, 95% CI\n[−4.60,−2.80];p< 0.001)), liver (APC=−3.40, 95% CI [−3.50,\n−3.3",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "site": "brain",
    "metricName": null,
    "value": 2040,
    "unit": "%",
    "notes": "Our analyses predict a\ndecrease in metastases to lung ((APC (2019–2030)=−1.90, 95%\nCI [−2.90,−1.00];p< 0.001), (2030–2040)=−3.70, 95% CI\n[−4.60,−2.80];p< 0.001)), liver (APC=−3.40, 95% CI [−3.50,\n−3.3",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "site": "brain",
    "metricName": null,
    "value": 33,
    "unit": null,
    "notes": "In past studies of syn-\nchronous metastases, lung primary tumors were the top con-\ntributor to metastases of the brain, bones, and lungs\n33–35",
    "pageHint": 5,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "site": "brain",
    "metricName": null,
    "value": 35,
    "unit": null,
    "notes": "In past studies of syn-\nchronous metastases, lung primary tumors were the top con-\ntributor to metastases of the brain, bones, and lungs\n33–35",
    "pageHint": 5,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "site": "lung",
    "metricName": null,
    "value": null,
    "unit": "year",
    "notes": "The epidemiology of lung metastases.Front",
    "pageHint": 6,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "site": "bone",
    "metricName": null,
    "value": null,
    "unit": "year",
    "notes": "Epidemiology of bone metastases.Bone1, 115783 (2020)",
    "pageHint": 6,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "site": "brain",
    "metricName": null,
    "value": null,
    "unit": "year",
    "notes": "Epidemiology of synchronous brain metastases.Neurooncol",
    "pageHint": 6,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "site": "lung",
    "metricName": null,
    "value": 605,
    "unit": null,
    "notes": "The epidemiology of lung metastases.Front",
    "pageHint": 6,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "site": "lung",
    "metricName": null,
    "value": 644,
    "unit": null,
    "notes": "The epidemiology of lung metastases.Front",
    "pageHint": 6,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "site": "lung",
    "metricName": null,
    "value": 2011,
    "unit": null,
    "notes": "The epidemiology of lung metastases.Front",
    "pageHint": 6,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "site": "lung",
    "metricName": null,
    "value": 33,
    "unit": null,
    "notes": "The epidemiology of lung metastases.Front",
    "pageHint": 6,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "site": "bone",
    "metricName": null,
    "value": 723396,
    "unit": null,
    "notes": "Epidemiology of bone metastases.Bone1, 115783 (2020)",
    "pageHint": 6,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "site": "bone",
    "metricName": null,
    "value": 2021,
    "unit": null,
    "notes": "Epidemiology of bone metastases.Bone1, 115783 (2020)",
    "pageHint": 6,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "site": "bone",
    "metricName": null,
    "value": 34,
    "unit": null,
    "notes": "Epidemiology of bone metastases.Bone1, 115783 (2020)",
    "pageHint": 6,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "site": "brain",
    "metricName": null,
    "value": 115783,
    "unit": null,
    "notes": "Epidemiology of synchronous brain metastases.Neurooncol",
    "pageHint": 6,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "site": "brain",
    "metricName": null,
    "value": 2020,
    "unit": null,
    "notes": "Epidemiology of synchronous brain metastases.Neurooncol",
    "pageHint": 6,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-004",
    "filename": "Hudock_et_al.pdf",
    "site": "brain",
    "metricName": null,
    "value": 35,
    "unit": null,
    "notes": "Epidemiology of synchronous brain metastases.Neurooncol",
    "pageHint": 6,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-007",
    "filename": "Xiao_et_al.pdf",
    "site": "lung",
    "metricName": null,
    "value": 77,
    "unit": "%",
    "notes": "In  autopsy  studies  on  \nmetastatic  patterns  of  breast  cancer,  57–77%  of  patients  \nwere  found  to  have  lung  metastases  [3]",
    "pageHint": 1,
    "needsManualReview": false
  },
  {
    "sourceRefId": "ref-007",
    "filename": "Xiao_et_al.pdf",
    "site": "lung",
    "metricName": null,
    "value": 1.8,
    "unit": "%",
    "notes": "Four thou-\nsand  two  hundred  and  thirteen  lung  metastatic  patients  \nwere  identified,  accounting  for  1.8%  and  36.4%  of  the  \nentire study cohort and subgroup with distant metastases, \nre",
    "pageHint": 1,
    "needsManualReview": false
  },
  {
    "sourceRefId": "ref-007",
    "filename": "Xiao_et_al.pdf",
    "site": "lung",
    "metricName": null,
    "value": 36.4,
    "unit": "%",
    "notes": "Four thou-\nsand  two  hundred  and  thirteen  lung  metastatic  patients  \nwere  identified,  accounting  for  1.8%  and  36.4%  of  the  \nentire study cohort and subgroup with distant metastases, \nre",
    "pageHint": 1,
    "needsManualReview": false
  },
  {
    "sourceRefId": "ref-007",
    "filename": "Xiao_et_al.pdf",
    "site": "lung",
    "metricName": null,
    "value": 1.8,
    "unit": "%",
    "notes": "Four thou-\nsand  two  hundred  and  thirteen  lung  metastatic  patients  \nwere  identified,  accounting  for  1.8%  and  36.4%  of  the  \nentire study cohort and subgroup with distant metastases, \nre",
    "pageHint": 1,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-007",
    "filename": "Xiao_et_al.pdf",
    "site": "lung",
    "metricName": null,
    "value": 36.4,
    "unit": "%",
    "notes": "Four thou-\nsand  two  hundred  and  thirteen  lung  metastatic  patients  \nwere  identified,  accounting  for  1.8%  and  36.4%  of  the  \nentire study cohort and subgroup with distant metastases, \nre",
    "pageHint": 1,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-007",
    "filename": "Xiao_et_al.pdf",
    "site": "lung",
    "metricName": null,
    "value": 57,
    "unit": "%",
    "notes": "In  autopsy  studies  on  \nmetastatic  patterns  of  breast  cancer,  57–77%  of  patients  \nwere  found  to  have  lung  metastases  [3]",
    "pageHint": 1,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-007",
    "filename": "Xiao_et_al.pdf",
    "site": "lung",
    "metricName": null,
    "value": 77,
    "unit": "%",
    "notes": "In  autopsy  studies  on  \nmetastatic  patterns  of  breast  cancer,  57–77%  of  patients  \nwere  found  to  have  lung  metastases  [3]",
    "pageHint": 1,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-007",
    "filename": "Xiao_et_al.pdf",
    "site": "lung",
    "metricName": null,
    "value": 36,
    "unit": "%",
    "notes": "Four thou-\nsand  two  hundred  and  thirteen  lung  metastatic  patients  \nwere  identified,  accounting  for  1.8%  and  36.4%  of  the  \nentire study cohort and subgroup with distant metastases, \nre",
    "pageHint": 1,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-007",
    "filename": "Xiao_et_al.pdf",
    "site": "lung",
    "metricName": null,
    "value": 1214,
    "unit": null,
    "notes": "Of  these,  1214  were  patients  with  metastases  \nconfined  to  lungs  (i.e.,  metastatic  disease  only  in  the  \nlungs)",
    "pageHint": 1,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-007",
    "filename": "Xiao_et_al.pdf",
    "site": "lung",
    "metricName": null,
    "value": 1.2,
    "unit": "%",
    "notes": "Xiao et al.Breast Cancer and Lung Metastases\nHR\n+\n/HER2\n−\n  subtype  (1.2%  of  the  entire  study  popula-\ntion,  31.8%  of  the  metastatic  subgroup)  the  lowest",
    "pageHint": 2,
    "needsManualReview": false
  },
  {
    "sourceRefId": "ref-007",
    "filename": "Xiao_et_al.pdf",
    "site": "lung",
    "metricName": null,
    "value": 31.8,
    "unit": "%",
    "notes": "Xiao et al.Breast Cancer and Lung Metastases\nHR\n+\n/HER2\n−\n  subtype  (1.2%  of  the  entire  study  popula-\ntion,  31.8%  of  the  metastatic  subgroup)  the  lowest",
    "pageHint": 2,
    "needsManualReview": false
  },
  {
    "sourceRefId": "ref-007",
    "filename": "Xiao_et_al.pdf",
    "site": "lung",
    "metricName": null,
    "value": 95,
    "unit": "%",
    "notes": "0  or  1  site;  OR,  1.30;  95%  CI:  1.18–1.44;  P  <  0.001)  \nand  three  metastatic  sites  outside  of  lungs  (vs",
    "pageHint": 2,
    "needsManualReview": false
  },
  {
    "sourceRefId": "ref-007",
    "filename": "Xiao_et_al.pdf",
    "site": "lung",
    "metricName": null,
    "value": 1.2,
    "unit": "%",
    "notes": "Xiao et al.Breast Cancer and Lung Metastases\nHR\n+\n/HER2\n−\n  subtype  (1.2%  of  the  entire  study  popula-\ntion,  31.8%  of  the  metastatic  subgroup)  the  lowest",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-007",
    "filename": "Xiao_et_al.pdf",
    "site": "lung",
    "metricName": null,
    "value": 31.8,
    "unit": "%",
    "notes": "Xiao et al.Breast Cancer and Lung Metastases\nHR\n+\n/HER2\n−\n  subtype  (1.2%  of  the  entire  study  popula-\ntion,  31.8%  of  the  metastatic  subgroup)  the  lowest",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-007",
    "filename": "Xiao_et_al.pdf",
    "site": "lung",
    "metricName": null,
    "value": 1.3,
    "unit": "%",
    "notes": "0  or  1  site;  OR,  1.30;  95%  CI:  1.18–1.44;  P  <  0.001)  \nand  three  metastatic  sites  outside  of  lungs  (vs",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-007",
    "filename": "Xiao_et_al.pdf",
    "site": "lung",
    "metricName": null,
    "value": 1.18,
    "unit": "%",
    "notes": "0  or  1  site;  OR,  1.30;  95%  CI:  1.18–1.44;  P  <  0.001)  \nand  three  metastatic  sites  outside  of  lungs  (vs",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-007",
    "filename": "Xiao_et_al.pdf",
    "site": "lung",
    "metricName": null,
    "value": 1.44,
    "unit": "%",
    "notes": "0  or  1  site;  OR,  1.30;  95%  CI:  1.18–1.44;  P  <  0.001)  \nand  three  metastatic  sites  outside  of  lungs  (vs",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-007",
    "filename": "Xiao_et_al.pdf",
    "site": "lung",
    "metricName": null,
    "value": 0.001,
    "unit": "%",
    "notes": "0  or  1  site;  OR,  1.30;  95%  CI:  1.18–1.44;  P  <  0.001)  \nand  three  metastatic  sites  outside  of  lungs  (vs",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-007",
    "filename": "Xiao_et_al.pdf",
    "site": "lung",
    "metricName": null,
    "value": 31,
    "unit": "%",
    "notes": "Xiao et al.Breast Cancer and Lung Metastases\nHR\n+\n/HER2\n−\n  subtype  (1.2%  of  the  entire  study  popula-\ntion,  31.8%  of  the  metastatic  subgroup)  the  lowest",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-007",
    "filename": "Xiao_et_al.pdf",
    "site": "lung",
    "metricName": null,
    "value": 30,
    "unit": "%",
    "notes": "0  or  1  site;  OR,  1.30;  95%  CI:  1.18–1.44;  P  <  0.001)  \nand  three  metastatic  sites  outside  of  lungs  (vs",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-007",
    "filename": "Xiao_et_al.pdf",
    "site": "lung",
    "metricName": null,
    "value": 95,
    "unit": "%",
    "notes": "0  or  1  site;  OR,  1.30;  95%  CI:  1.18–1.44;  P  <  0.001)  \nand  three  metastatic  sites  outside  of  lungs  (vs",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-007",
    "filename": "Xiao_et_al.pdf",
    "site": "lung",
    "metricName": null,
    "value": 18,
    "unit": "%",
    "notes": "0  or  1  site;  OR,  1.30;  95%  CI:  1.18–1.44;  P  <  0.001)  \nand  three  metastatic  sites  outside  of  lungs  (vs",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-007",
    "filename": "Xiao_et_al.pdf",
    "site": "lung",
    "metricName": null,
    "value": 44,
    "unit": "%",
    "notes": "0  or  1  site;  OR,  1.30;  95%  CI:  1.18–1.44;  P  <  0.001)  \nand  three  metastatic  sites  outside  of  lungs  (vs",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-007",
    "filename": "Xiao_et_al.pdf",
    "site": "lung",
    "metricName": null,
    "value": 1,
    "unit": "%",
    "notes": "0  or  1  site;  OR,  1.30;  95%  CI:  1.18–1.44;  P  <  0.001)  \nand  three  metastatic  sites  outside  of  lungs  (vs",
    "pageHint": 2,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-007",
    "filename": "Xiao_et_al.pdf",
    "site": "lung",
    "metricName": null,
    "value": 17,
    "unit": "%",
    "notes": "[13]  observed  that  the  \nfrequency  of  lung  metastases  in  each  breast  cancer  subtype  \nwas  17%,  14%,  25%,  and  31%,  respectively,  in  a  cohort  \nof  531  consecutive  patients  with  ",
    "pageHint": 5,
    "needsManualReview": false
  },
  {
    "sourceRefId": "ref-007",
    "filename": "Xiao_et_al.pdf",
    "site": "lung",
    "metricName": null,
    "value": 14,
    "unit": "%",
    "notes": "[13]  observed  that  the  \nfrequency  of  lung  metastases  in  each  breast  cancer  subtype  \nwas  17%,  14%,  25%,  and  31%,  respectively,  in  a  cohort  \nof  531  consecutive  patients  with  ",
    "pageHint": 5,
    "needsManualReview": false
  },
  {
    "sourceRefId": "ref-007",
    "filename": "Xiao_et_al.pdf",
    "site": "lung",
    "metricName": null,
    "value": 25,
    "unit": "%",
    "notes": "[13]  observed  that  the  \nfrequency  of  lung  metastases  in  each  breast  cancer  subtype  \nwas  17%,  14%,  25%,  and  31%,  respectively,  in  a  cohort  \nof  531  consecutive  patients  with  ",
    "pageHint": 5,
    "needsManualReview": false
  },
  {
    "sourceRefId": "ref-007",
    "filename": "Xiao_et_al.pdf",
    "site": "lung",
    "metricName": null,
    "value": 31,
    "unit": "%",
    "notes": "[13]  observed  that  the  \nfrequency  of  lung  metastases  in  each  breast  cancer  subtype  \nwas  17%,  14%,  25%,  and  31%,  respectively,  in  a  cohort  \nof  531  consecutive  patients  with  ",
    "pageHint": 5,
    "needsManualReview": false
  },
  {
    "sourceRefId": "ref-007",
    "filename": "Xiao_et_al.pdf",
    "site": "lung",
    "metricName": null,
    "value": 11,
    "unit": "months",
    "notes": "Xiao et al.Breast Cancer and Lung Metastases\nof  lung  metastases  was  also  very  heterogeneous,  ranging  \nfrom     11.0     months     of     triple-     negative     subtypes     to     \n31.0  mo",
    "pageHint": 5,
    "needsManualReview": false
  },
  {
    "sourceRefId": "ref-007",
    "filename": "Xiao_et_al.pdf",
    "site": "lung",
    "metricName": null,
    "value": 31,
    "unit": "months",
    "notes": "Xiao et al.Breast Cancer and Lung Metastases\nof  lung  metastases  was  also  very  heterogeneous,  ranging  \nfrom     11.0     months     of     triple-     negative     subtypes     to     \n31.0  mo",
    "pageHint": 5,
    "needsManualReview": false
  },
  {
    "sourceRefId": "ref-007",
    "filename": "Xiao_et_al.pdf",
    "site": "lung",
    "metricName": null,
    "value": 11,
    "unit": "months",
    "notes": "Xiao et al.Breast Cancer and Lung Metastases\nof  lung  metastases  was  also  very  heterogeneous,  ranging  \nfrom     11.0     months     of     triple-     negative     subtypes     to     \n31.0  mo",
    "pageHint": 5,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-007",
    "filename": "Xiao_et_al.pdf",
    "site": "lung",
    "metricName": null,
    "value": 31,
    "unit": "months",
    "notes": "Xiao et al.Breast Cancer and Lung Metastases\nof  lung  metastases  was  also  very  heterogeneous,  ranging  \nfrom     11.0     months     of     triple-     negative     subtypes     to     \n31.0  mo",
    "pageHint": 5,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-007",
    "filename": "Xiao_et_al.pdf",
    "site": "lung",
    "metricName": null,
    "value": 11,
    "unit": "months",
    "notes": "Xiao et al.Breast Cancer and Lung Metastases\nof  lung  metastases  was  also  very  heterogeneous,  ranging  \nfrom     11.0     months     of     triple-     negative     subtypes     to     \n31.0  mo",
    "pageHint": 5,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-007",
    "filename": "Xiao_et_al.pdf",
    "site": "lung",
    "metricName": null,
    "value": 31,
    "unit": "months",
    "notes": "Xiao et al.Breast Cancer and Lung Metastases\nof  lung  metastases  was  also  very  heterogeneous,  ranging  \nfrom     11.0     months     of     triple-     negative     subtypes     to     \n31.0  mo",
    "pageHint": 5,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-007",
    "filename": "Xiao_et_al.pdf",
    "site": "lung",
    "metricName": null,
    "value": 13,
    "unit": "%",
    "notes": "[13]  observed  that  the  \nfrequency  of  lung  metastases  in  each  breast  cancer  subtype  \nwas  17%,  14%,  25%,  and  31%,  respectively,  in  a  cohort  \nof  531  consecutive  patients  with  ",
    "pageHint": 5,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-007",
    "filename": "Xiao_et_al.pdf",
    "site": "lung",
    "metricName": null,
    "value": 17,
    "unit": "%",
    "notes": "[13]  observed  that  the  \nfrequency  of  lung  metastases  in  each  breast  cancer  subtype  \nwas  17%,  14%,  25%,  and  31%,  respectively,  in  a  cohort  \nof  531  consecutive  patients  with  ",
    "pageHint": 5,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-007",
    "filename": "Xiao_et_al.pdf",
    "site": "lung",
    "metricName": null,
    "value": 14,
    "unit": "%",
    "notes": "[13]  observed  that  the  \nfrequency  of  lung  metastases  in  each  breast  cancer  subtype  \nwas  17%,  14%,  25%,  and  31%,  respectively,  in  a  cohort  \nof  531  consecutive  patients  with  ",
    "pageHint": 5,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-007",
    "filename": "Xiao_et_al.pdf",
    "site": "lung",
    "metricName": null,
    "value": 25,
    "unit": "%",
    "notes": "[13]  observed  that  the  \nfrequency  of  lung  metastases  in  each  breast  cancer  subtype  \nwas  17%,  14%,  25%,  and  31%,  respectively,  in  a  cohort  \nof  531  consecutive  patients  with  ",
    "pageHint": 5,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-007",
    "filename": "Xiao_et_al.pdf",
    "site": "lung",
    "metricName": null,
    "value": 31,
    "unit": "%",
    "notes": "[13]  observed  that  the  \nfrequency  of  lung  metastases  in  each  breast  cancer  subtype  \nwas  17%,  14%,  25%,  and  31%,  respectively,  in  a  cohort  \nof  531  consecutive  patients  with  ",
    "pageHint": 5,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-007",
    "filename": "Xiao_et_al.pdf",
    "site": "lung",
    "metricName": null,
    "value": 531,
    "unit": "%",
    "notes": "[13]  observed  that  the  \nfrequency  of  lung  metastases  in  each  breast  cancer  subtype  \nwas  17%,  14%,  25%,  and  31%,  respectively,  in  a  cohort  \nof  531  consecutive  patients  with  ",
    "pageHint": 5,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-007",
    "filename": "Xiao_et_al.pdf",
    "site": "lung",
    "metricName": null,
    "value": null,
    "unit": "year",
    "notes": "Clinical  course  of  breast  cancer  patients  with  metastases  \nconfined  to  the  lungs  treated  with  chemotherapy",
    "pageHint": 7,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-007",
    "filename": "Xiao_et_al.pdf",
    "site": "lung",
    "metricName": null,
    "value": 1998,
    "unit": null,
    "notes": "Clinical  course  of  breast  cancer  patients  with  metastases  \nconfined  to  the  lungs  treated  with  chemotherapy",
    "pageHint": 7,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-007",
    "filename": "Xiao_et_al.pdf",
    "site": "lung",
    "metricName": null,
    "value": null,
    "unit": "year",
    "notes": "Favourable  long-  \nterm  results  after  surgical  removal  of  lung  metastases  \nof  breast  cancer",
    "pageHint": 8,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-007",
    "filename": "Xiao_et_al.pdf",
    "site": "metastases",
    "metricName": null,
    "value": null,
    "unit": "year",
    "notes": "Surgical  approach  to  \npulmonary  metastases  from  breast  cancer",
    "pageHint": 8,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-007",
    "filename": "Xiao_et_al.pdf",
    "site": "lung",
    "metricName": null,
    "value": 15,
    "unit": null,
    "notes": "Xiao et al.Breast Cancer and Lung Metastases\n15",
    "pageHint": 8,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-007",
    "filename": "Xiao_et_al.pdf",
    "site": "lung",
    "metricName": null,
    "value": 2008,
    "unit": null,
    "notes": "Favourable  long-  \nterm  results  after  surgical  removal  of  lung  metastases  \nof  breast  cancer",
    "pageHint": 8,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-007",
    "filename": "Xiao_et_al.pdf",
    "site": "metastases",
    "metricName": null,
    "value": 35,
    "unit": null,
    "notes": "Surgical  approach  to  \npulmonary  metastases  from  breast  cancer",
    "pageHint": 8,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-007",
    "filename": "Xiao_et_al.pdf",
    "site": "metastases",
    "metricName": null,
    "value": 393,
    "unit": null,
    "notes": "Surgical  approach  to  \npulmonary  metastases  from  breast  cancer",
    "pageHint": 8,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-007",
    "filename": "Xiao_et_al.pdf",
    "site": "metastases",
    "metricName": null,
    "value": 397,
    "unit": null,
    "notes": "Surgical  approach  to  \npulmonary  metastases  from  breast  cancer",
    "pageHint": 8,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-007",
    "filename": "Xiao_et_al.pdf",
    "site": "metastases",
    "metricName": null,
    "value": 19,
    "unit": null,
    "notes": "Surgical  approach  to  \npulmonary  metastases  from  breast  cancer",
    "pageHint": 8,
    "needsManualReview": true
  },
  {
    "sourceRefId": "ref-007",
    "filename": "Xiao_et_al.pdf",
    "site": "metastases",
    "metricName": null,
    "value": 2012,
    "unit": null,
    "notes": "Surgical  approach  to  \npulmonary  metastases  from  breast  cancer",
    "pageHint": 8,
    "needsManualReview": true
  }
]